Original Articles

• Advances in immunology and rheumatoid arthritis pathogenesis

  G. Valesini, F. Barone, D. Bompanone, M. Catuogno, A. Sili Scavalli

  9-20

  https://doi.org/10.4081/reumatismo.2004.1s.9

  1993

• Outcome predictors in rheumatoid arthritis

  C. Montecucco

  21-27

  https://doi.org/10.4081/reumatismo.2004.1s.21

  889

  PDF: 943

  • PDF

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  962

  PDF: 2929

  • PDF

• IL-1Ra: its role in rheumatoid arthritis

  M. Cutolo

  41-45

  https://doi.org/10.4081/reumatismo.2004.1s.41

  1462

  PDF: 2290

  • PDF

• Reconstructing the pyramid as a therapeutic approach to rheumatoid arthritis

  G. Ferraccioli

  46-50

  https://doi.org/10.4081/reumatismo.2004.1s.46

  687

  PDF: 675

  • PDF

• Therapeutic gene transfer for rheumatoid arthritis

  M.C. Boissier, N. Bessis

  51-61

  https://doi.org/10.4081/reumatismo.2004.1s.51

  699

  PDF: 691

  • PDF

• IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy

  U. Fiocco, M. Vezzù, L. Cozzi, S. Todesco

  62-73

  https://doi.org/10.4081/reumatismo.2004.1s.62

  1268

  PDF: 1907

  • PDF

• The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis

  L. Riente

  74-79

  https://doi.org/10.4081/reumatismo.2004.1s.74

  745

  PDF: 887

  • PDF

• Farmacoeconomic impact of anti-TNFα

  G. Leardini, C. Bernardi, E. Vaccaro

  80-86

  https://doi.org/10.4081/reumatismo.2004.1s.80

  831

  PDF: 642

  • PDF

• Disability and quality of life of patients with rheumatoid arthritis: assessment and perspectives

  F. Salaffi, A. Stancati

  87-106

  https://doi.org/10.4081/reumatismo.2004.1s.87

  1281

  PDF: 3356

  • PDF